Adenocarcinoma Of Lung Response To Tyrosine Kinase Inhibitor In Somatic C1851577
A type of lung cancer that may respond to targeted drugs called tyrosine kinase inhibitors when specific genetic mutations are present. Treatment involves genetic testing of the tumor and appropriate targeted therapy, often used alongside other treatments.
Key facts at a glance
- ICD-10
- J98.9
- ICD-11
- CA00.0
- Body system
- respiratory
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Chest pain
Cough
(respiratory)Shortness of breath or cough
(respiratory)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Dyspnea
(respiratory)Hemoptysis
(respiratory)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Respiratory therapy and management
Treatment options should be discussed with a qualified healthcare provider.
Targeted Tyrosine Kinase Inhibitor Therapy
Specific TKIs based on molecular profiling of the tumor target driver mutations in EGFR, ALK, ROS1, or other actionable alterations. Continuous daily dosing maintains therapeutic levels and suppresses tumor growth through inhibition of cancer cell signaling pathways.
Serial Imaging and Tumor Marker Surveillance
Regular CT, MRI, or PET scans combined with relevant tumor markers track treatment response and detect early progression. Imaging schedules are typically every 2-3 months during active treatment to assess ongoing efficacy.
Additional treatment options
Liquid Biopsy for Resistance Mutation Testing
Blood-based circulating tumor DNA testing identifies emerging resistance mutations when progression occurs, guiding selection of next-line targeted therapies or combination approaches without requiring invasive tissue biopsy.
procedureNext-Generation TKI or Combination Therapy
Upon progression, escalation to next-generation targeted agents or combination strategies including chemotherapy, immunotherapy, or anti-angiogenic agents may be considered based on resistance mechanisms and prior treatment history.
medicationWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Adenocarcinoma Of Lung Response To Tyrosine Kinase Inhibitor In Somatic C1851577?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Ramalingam SS, Yang JC, Lee CK, et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J Clin Oncol. 2020.
Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017.
Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin/pemetrexed for metastatic non-small-cell lung cancer with EGFR mutations. J Clin Oncol. 2013.
Lee CK, Davies M, Wu YL, et al. Lung cancer with EGFR mutations: systematic review and meta-analysis of survival outcomes. J Thorac Oncol. 2017.
Medication Comparisons
Compare medications used to treat Adenocarcinoma Of Lung Response To Tyrosine Kinase Inhibitor In Somatic C1851577. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy